Renovis Ends Phase Ia Clinical Trial with REN-850

Renovis has ended its Phase Ia clinical trial for REN-850, an investigational small molecule that was being studied for the treatment of multiple sclerosis (MS).

The objective of this study was to assess the safety, tolerability and pharmacokinetics of escalating single doses of REN-850 in healthy volunteers. Based on preclinical studies REN-850 is believed to act by inhibition of leukocyte trafficking.